Niaspan Antitrust Litigation
Niaspan is an extended-release niacin formulation used to treat dyslipidemia and reduce cardiovascular risk by lowering LDL cholesterol and triglycerides while increasing HDL cholesterol. Its regulatory history includes FDA approval in 1997, patent protections until around 2014, and subsequent entry of generic versions. The drug's market exclusivity and patent status are central to the antitrust allegations, which involve delayed generic entry to maintain high prices.
20
Pending actions
23
Total actions filed
Active
Status
09/17/2013
Established
Filing deadline
No specific filing deadlines or statutes of limitations are publicly available as of March 2026.
Who qualifies
Plaintiffs must demonstrate that they purchased Niaspan during the period of alleged anticompetitive conduct and that their prices were inflated due to delayed generic entry caused by the settlement agreements. Individual proof of damages and causation is required following the denial of class certification for end-payors.
Products involved
- Niaspan (brand), Niacin (generic)
Alleged injuries
- Inflated drug prices due to delayed generic competition, leading to economic harm for consumers and third-party payors.
Bellwether trials
No recent bellwether trials or verdicts have been publicly reported as of March 2026. The case remains active with ongoing case management activities, but no scheduled trials or settlements are publicly documented.
Lead counsel
- Berger Montague
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
